Selection of the optimal reperfusion strategy for STEMI: does time matter?

doi:10.1093/eurheartj/ehi775

European Heart Journal Advance Access published online on March 2, 2006
European Heart Journal, doi:10.1093/eurheartj/ehi775

This Article

	Full Text (Rapid PDF)
	All Versions of this Article: 27/7/761 most recent ehi775v1
	E-letters: Submit a response
	Alert me when this article is cited
	Alert me when E-letters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Request Permissions
	Disclaimer

Google Scholar

	Articles by Gersh, B. J.
	Articles by Antman, E. M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Gersh, B. J.
	Articles by Antman, E. M.

Social Bookmarking

	What's this?

Editorial

Selection of the optimal reperfusion strategy for STEMI: does time matter?

Bernard J. Gersh ¹ ^* and Elliott M. Antman ²

¹ Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
² Samuel A. Levine Cardiac Unit, Harvard Medical School, Brigham and Women's Hospital, Cardiovascular Division, 75 Francis Street, Boston, MA 02115, USA

^* To whom correspondence should be addressed.
Bernard J. Gersh, E-mail: gersh.bernard{at}mayo.edu

This article has no Abstract.

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

CiteULike

Connotea

Del.icio.us What's this?

This article has been cited by other articles:

E. M. Antman
Time Is Muscle: Translation Into Practice
J. Am. Coll. Cardiol., October 7, 2008; 52(15): 1216 - 1221.
[Abstract] [Full Text] [PDF]

M. P. Gulseth, J. Michaud, and E. A. Nutescu
Rivaroxaban: An oral direct inhibitor of factor Xa
Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1520 - 1529.
[Abstract] [Full Text] [PDF]

E. R. Bates and B. K. Nallamothu
Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction
Circulation, July 29, 2008; 118(5): 567 - 573.
[Full Text] [PDF]

J. I. Weitz, J. Hirsh, and M. M. Samama
New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 234S - 256S.
[Abstract] [Full Text] [PDF]

A. G.G. Turpie
New oral anticoagulants in atrial fibrillation
Eur. Heart J., January 2, 2008; 29(2): 155 - 165.
[Abstract] [Full Text] [PDF]

W. E. Boden, K. Eagle, and C. B. Granger
Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options
J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929.
[Abstract] [Full Text] [PDF]

G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong, and for the ODIXa-DVT Study Investigators
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
Circulation, July 10, 2007; 116(2): 180 - 187.
[Abstract] [Full Text] [PDF]

J. W. Eikelboom and J. I. Weitz
A Replacement for Warfarin: The Search Continues
Circulation, July 10, 2007; 116(2): 131 - 133.
[Full Text] [PDF]

A. G.G. Turpie
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1238 - 1247.
[Abstract] [Full Text] [PDF]

				M. P. Gulseth, J. Michaud, and E. A. Nutescu Rivaroxaban: An oral direct inhibitor of factor Xa Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1520 - 1529. [Abstract] [Full Text] [PDF]

				E. R. Bates and B. K. Nallamothu Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction Circulation, July 29, 2008; 118(5): 567 - 573. [Full Text] [PDF]

				J. I. Weitz, J. Hirsh, and M. M. Samama New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 234S - 256S. [Abstract] [Full Text] [PDF]

				A. G.G. Turpie New oral anticoagulants in atrial fibrillation Eur. Heart J., January 2, 2008; 29(2): 155 - 165. [Abstract] [Full Text] [PDF]

				W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF]

				G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong, and for the ODIXa-DVT Study Investigators Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study Circulation, July 10, 2007; 116(2): 180 - 187. [Abstract] [Full Text] [PDF]

				J. W. Eikelboom and J. I. Weitz A Replacement for Warfarin: The Search Continues Circulation, July 10, 2007; 116(2): 131 - 133. [Full Text] [PDF]

				A. G.G. Turpie Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1238 - 1247. [Abstract] [Full Text] [PDF]